John Hall

John Hall, Ph.D., is a Principal Scientist at Dyne Therapeutics, where expertise in drug candidate selection for Duchenne Muscular Dystrophy (DMD) has been demonstrated through leadership in ASO technology development, successful FDA IND approval for DYNE-251, and the establishment of advanced imaging modalities. Previous experience includes Senior Scientist roles at Capricor Therapeutics, focusing on therapeutic exosome delivery for neuromuscular applications and development of skeletal muscle assays, as well as a tenure at Caltech managing high sensitivity imaging technology. Academic background includes extensive research on stem cell function during aging and disease, culminating in a Ph.D. from the University of Colorado Boulder.